Trulicity works in three ways to help lower blood glucose in a once-weekly dose.1

Trulicity acts like the natural human hormone, GLP-1, helping the body do what it’s supposed to do naturally.1

[Illustrations of body with highlighted organs: stomach, liver, pancreas]
  • Reduces hepatic glucose production by decreasing glucagon secretion

  • Slows gastric emptying

  • Glucose-dependent insulin release

  • Reduces hepatic glucose production by decreasing glucagon secretion
  • Slows gastric emptying
  • Glucose-dependent insulin release

Mechanism of Action

See how Trulicity was designed with patients in mind.

Both fasting and postprandial hyperglycemia contribute to overall hyperglycemia2

Study description
[Bar chart of fasting and postprandial contribution to A1C]

Reduction in fasting and postprandial glucose at 48 hours after first dose of Trulicity1,3-5

These data are from a pharmacodynamics study.

FSG = fasting serum glucose.

PPG = postprandial serum glucose

Data presented are secondary endpoints

Study description
[Bar chart of fasting and postprandial contribution to A1C]

The 2018 ADA/EASD consensus report recommends considering a GLP-1 RA in most patients with type 2 diabetes prior to insulin*6

*After oral medication in patients with no symptoms of hyperglycemia.

Consider insulin as first injectable if

  • A1C >11%
  • Symptoms or evidence of catabolism: weight loss, polyuria, or polydipsia, which suggest insulin deficiency
  • Type 1 diabetes is a possibility

See the abridged American Diabetes Association therapy recommendations for patients with type 2 diabetes here.

Study Descriptions

Study description for the relative contribution of fasting and postprandial plasma glucose to overall hyperglycemia2

  • 290 noninsulin, nonacarbose treated patients with type 2 diabetes were enrolled in this study
  • Plasma glucose (PG) data was collected at 8 am, 11 am, 2 pm, and 5 pm
  • Area under the curve above fasting PG (AUC1) was used as a measure of postprandial glucose increments and AUC2-AUC1 as a measure of fasting glucose increments where AUC2 is area under the curve above 6.1 mmol/L
  • Relative contribution of postprandial and fasting plasma glucose increments to overall diurnal hyperglycemia was assessed for each quintile of baseline A1C

Study description for pharmacodynamics data1,3-5

  • 6-week, multicenter, parallel-design, double-blind, part-randomized, placebo-controlled, multiple-dose, phase 1 study in patients ≥65 years old with type 2 diabetes treated with oral antihyperglycemic medications except sulfonylureas, disaccharidase inhibitors, and meglitinides
  • Study arms included placebo (n=8); Trulicity 0.5 mg (n=9), not a marketed dose; Trulicity 0.75 (n=11); and Trulicity 1.5 mg (n=9)
  • Primary objective was to evaluate the safety and tolerability of Trulicity 0.5 mg, 0.75 mg, and 1.5 mg for 6 weeks; mixed effect linear model; primary objective met
  • Data presented are LS mean change from baseline and are secondary endpoints

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Back to top